2023
736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies
Moser J, Sullivan R, Taylor M, Puzanov I, Falchook G, Sznol M, Paton V, Chonzi D, Garofalo B, Sonnemann M, Uppal H, Barton J, McQueen B, Ring A, Kluger H. 736 A phase 1/2 open-label, dose-escalation study of ST-067, a decoy-resistant IL-18 cytokine, given as a monotherapy and with pembrolizumab in advanced solid tumor malignancies. 2023, a829-a829. DOI: 10.1136/jitc-2023-sitc2023.0736.Peer-Reviewed Original Research
2022
789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)
Sarnaik A, Lewis K, Kluger H, Hamid O, Whitman E, Thomas S, Wermke M, Cusnir M, Domingo-Musibay E, Phan G, Kirkwood J, Hassel J, Orloff M, Larkin J, Weber J, Furness A, Khushalani N, Medina T, Finckenstein F, Jagasia M, Hari P, Sulur G, Shi W, Wu X, Chesney J. 789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study). 2022, a821-a822. DOI: 10.1136/jitc-2022-sitc2022.0789.Peer-Reviewed Original ResearchUnilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab
Sanchez A, Kahn P, Minerowicz C, Kluger H. Unilateral Pneumonitis and Hydropneumothorax Following Pembrolizumab. Journal Of Brown Hospital Medicine 2022, 2 DOI: 10.56305/001c.39747.Peer-Reviewed Case Reports and Technical NotesCheckpoint inhibitor pneumonitisTransbronchial biopsy resultsBronchoalveolar lavage fluidProgressive dyspneaDry coughPembrolizumab monotherapyLavage fluidRadiographic findingsBiopsy resultsMetastatic melanomaPleural fluidPneumonitisHydropneumothoraxPembrolizumabDyspneaMonotherapyCoughPneumoniaMelanomaSymptomsInfectionWeeks